-
Study aim
-
To determine the efficacy and safety of postoperative nebulized ketamine in reducing pain and improving recovery outcomes after tonsillectomy in children, aiming to provide evidence for an opioid-sparing analgesic strategy in pediatric surgery.
-
Design
-
Prospective, randomized, double-blind, placebo-controlled clinical trial
Randomization:
Stratified block randomization (1:1 allocation) into Group K (nebulized ketamine) or Group P (placebo), stratified by age (5-7 vs. 8-12 years) to minimize confounding. Computer-generated sequence stored securely by a research pharmacist; allocation concealed using opaque, sealed envelopes.
Blinding:
Double-blind. Patients, parents/guardians, clinicians (surgeons, anesthesiologists, nurses), and outcome assessors blinded. Nebulized ketamine and saline prepared in identical vials/syringes, labeled with unique study numbers, indistinguishable in appearance.
-
Settings and conduct
-
Taleghani care university hospital’s pediatric surgical ward and PACU.
Patients, parents/guardians, clinicians (surgeons, anesthesiologists, nurses), and outcome assessors blinded.
-
Participants/Inclusion and exclusion criteria
-
Inclusion: ASA I-II, no ketamine allergy, no psychiatric/neurological disorders, chronic pain syndromes, severe asthma, or recent respiratory infections. Exclusion: Emergency surgery, recent opioid use.
-
Intervention groups
-
Nebulized ketamine (1 mg/kg, max 50 mg, diluted in 5 mL saline) administered via standard nebulizer device in the PACU, delivered over 10-15 minutes under continuous monitoring
-
Main outcome variables
-
To determine the efficacy and safety of postoperative nebulized ketamine in reducing pain and improving recovery outcomes after tonsillectomy in children, aiming to provide evidence for an opioid-sparing analgesic strategy in pediatric surgery.